Leukemia News

Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, explored clinical data on targeting p53-mutant hematologic malignancies in the presidential symposium at the ASH Annual Meeting and Exposition.

In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, talked about results from the phase 3 FLAIR study presented at ASH Annual Meeting and Exposition.

In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed updated data from the ALLIANCE study for chronic lymphocytic leukemia presented at ASH Annual Meeting and Exposition.

Upstream binding transcription factor tandem duplications, or UBTF-TDs, identified through integrated genomic analysis represent a new subtype of acute myeloid leukemia that previously had no known oncogenic driver, study results showed.

The combination of umbralisib and ublituximab demonstrated superior PFS and overall response rates compared with chemoimmunotherapy among patients with chronic lymphocytic leukemia and Bruton tyrosine kinase inhibitor risk factors.

Ibrutinib plus fludarabine, cyclophosphamide and rituximab, or FCR, yielded deep responses in younger patients with chronic lymphocytic leukemia over a median follow-up of 40 months.

In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed the randomized, phase 3 MAJIC trial, which he presented at ASH Annual Meeting and Exposition.

In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed the ReVenG trial, which was presented at ASH Annual Meeting and Exposition.

Minimal residual disease status appeared to influence outcomes after chimeric antigen receptor T-cell therapy for high-risk chronic lymphocytic leukemia, according to study results.

Sixty percent of hematologist-oncologists believe chimeric antigen receptor T-cell therapies provide clinical value at their current price, according to survey results presented at ASH Annual Meeting and Exposition.